BE900650A - Composition d'endotoxine detoxifiee raffinee et d'un extrait d'un microorganisme soluble dans la pyridine. - Google Patents

Composition d'endotoxine detoxifiee raffinee et d'un extrait d'un microorganisme soluble dans la pyridine.

Info

Publication number
BE900650A
BE900650A BE0/213703A BE213703A BE900650A BE 900650 A BE900650 A BE 900650A BE 0/213703 A BE0/213703 A BE 0/213703A BE 213703 A BE213703 A BE 213703A BE 900650 A BE900650 A BE 900650A
Authority
BE
Belgium
Prior art keywords
composition
extract
detoxified endotoxin
refined detoxified
microorganism
Prior art date
Application number
BE0/213703A
Other languages
English (en)
Inventor
J L Cantrell
Original Assignee
Ribi Immunochem Research Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ribi Immunochem Research Inc filed Critical Ribi Immunochem Research Inc
Publication of BE900650A publication Critical patent/BE900650A/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/74—Bacteria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/04—Mycobacterium, e.g. Mycobacterium tuberculosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/05—Actinobacteria, e.g. Actinomyces, Streptomyces, Nocardia, Bifidobacterium, Gardnerella, Corynebacterium; Propionibacterium
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/58—Medicinal preparations containing antigens or antibodies raising an immune response against a target which is not the antigen used for immunisation
    • A61K2039/585—Medicinal preparations containing antigens or antibodies raising an immune response against a target which is not the antigen used for immunisation wherein the target is cancer
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S530/00—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof
    • Y10S530/806—Antigenic peptides or proteins
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S530/00—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof
    • Y10S530/82—Proteins from microorganisms
    • Y10S530/825—Bacteria

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Mycology (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Microbiology (AREA)
  • Immunology (AREA)
  • Pulmonology (AREA)
  • Communicable Diseases (AREA)
  • Molecular Biology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Plant Substances (AREA)

Abstract

Composition pharmaceutique constituée d'un excipient, d'un extrait soluble dans la pyridine, purifié, d'un microorganisme et d'une endotoxine détoxifiée raffinée. La composition en question convient au traitement de tumeurs cancéreuses. On injecte la composition par la voie parentérale ou directement dans la tumeur.
BE0/213703A 1983-09-23 1984-09-21 Composition d'endotoxine detoxifiee raffinee et d'un extrait d'un microorganisme soluble dans la pyridine. BE900650A (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US06/535,037 US4663306A (en) 1983-09-23 1983-09-23 Pyridine-soluble extract-refined detoxified endotoxin composition and use

Publications (1)

Publication Number Publication Date
BE900650A true BE900650A (fr) 1985-03-21

Family

ID=24132594

Family Applications (1)

Application Number Title Priority Date Filing Date
BE0/213703A BE900650A (fr) 1983-09-23 1984-09-21 Composition d'endotoxine detoxifiee raffinee et d'un extrait d'un microorganisme soluble dans la pyridine.

Country Status (23)

Country Link
US (1) US4663306A (fr)
JP (1) JPS60120817A (fr)
KR (1) KR870000843B1 (fr)
AT (1) AT385659B (fr)
AU (1) AU566234B2 (fr)
BE (1) BE900650A (fr)
CA (1) CA1244765A (fr)
CH (1) CH664897A5 (fr)
DE (1) DE3434766C2 (fr)
DK (1) DK446684A (fr)
ES (1) ES8608872A1 (fr)
FI (1) FI843716L (fr)
FR (1) FR2552326B1 (fr)
GB (1) GB2149301B (fr)
HU (1) HU192585B (fr)
IL (1) IL73034A (fr)
IN (1) IN157240B (fr)
IT (1) IT1179444B (fr)
NL (1) NL8402902A (fr)
NO (1) NO843776L (fr)
NZ (1) NZ209635A (fr)
SE (1) SE8404707L (fr)
ZA (1) ZA847405B (fr)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4844894A (en) * 1984-07-12 1989-07-04 Ribi Immunochem Research Inc. Method of inhibiting the onset of septicemia and endotoxemia
US4806352A (en) * 1986-04-15 1989-02-21 Ribi Immunochem Research Inc. Immunological lipid emulsion adjuvant
US4877611A (en) * 1986-04-15 1989-10-31 Ribi Immunochem Research Inc. Vaccine containing tumor antigens and adjuvants
US4929604A (en) * 1986-05-28 1990-05-29 Board Of Regents, The University Of Texas System Lipopolysaccharides of reduced toxicity and the production thereof
EP0714305B1 (fr) * 1993-08-27 2001-12-19 Vetrepharm, Inc. Composition et procede servant a stimuler les capacites de reproduction
BE1007823A3 (fr) * 1993-12-10 1995-10-31 Anda Biolog Sa Utilisation d'une composition comprenant au moins un antigene et/ou un ou plusieurs fragments de cet antigene pour l'obtention d'un medicament destine au traitement et/ou a la prevention du cancer.
US6090385A (en) * 1993-12-10 2000-07-18 Maes; Hubert Method of treating cancer
US5976580A (en) 1995-06-07 1999-11-02 Novus International, Inc. Nutrient formulation and process for enhancing the health, livability, cumulative weight gain or feed efficiency in poultry and other animals
DE19710255A1 (de) * 1997-03-13 1998-09-17 Henkel Ecolab Gmbh & Co Ohg Verwendung einer Lösung zur Desaktivierung von Endotoxinen
JP4335435B2 (ja) 1997-08-05 2009-09-30 バイオニケ ライフ サイエンシーズ インコーポレイテッド 細胞増殖および細胞死を調節する組成物および方法
US6019985A (en) * 1998-02-27 2000-02-01 Munova Corporation Immunostimulation methods for providing disease protection in poultry
KR100628007B1 (ko) * 1998-07-16 2006-09-26 이치로 아즈마 세균의 균체성분을 유효성분으로 하는 암면역요법용 제제
AU785212B2 (en) * 1999-12-13 2006-11-09 Bioniche Life Sciences Inc. Therapeutically useful synthetic oligonucleotides
WO2001047561A1 (fr) * 1999-12-28 2001-07-05 Bioniche Life Sciences Inc. L'acide hyaluronique dans le traitement du cancer
RU2003104522A (ru) * 2000-07-11 2004-06-27 Байер Акциенгезельшафт (De) Применение штаммов parapoxvirus (парапокс-вируса) против органофиброзов
WO2003074079A1 (fr) * 2002-03-05 2003-09-12 Cell-Medicine, Inc. Adjuvant immunologique a base de tissus solidifies
JP4726485B2 (ja) * 2002-08-02 2011-07-20 大日本住友製薬株式会社 細菌細胞壁骨格成分製剤
FR2848223B1 (fr) * 2002-12-09 2005-02-25 Centre Nat Rech Scient Nouveau procede d'isolement des endotoxines.
WO2005023277A1 (fr) * 2003-09-05 2005-03-17 Shenyang Sunbellcom Bio-Pharmaceutical Co., Ltd. Composition a la base de squelettes de parois de cellules de nocardia rouge procede de preparation et son utilisation therapeutique pour traiter l'erosion cervicale
CA2564180A1 (fr) * 2004-04-22 2005-11-03 Dainippon Sumitomo Pharma Co., Ltd. Preparation pharmaceutique contenant un composant du squelette de la paroi de cellules bacteriennes
EP2986303B1 (fr) 2013-04-18 2020-02-26 Immune Design Corp. Monothérapie par gla pour une utilisation dans le traitement du cancer
US9463198B2 (en) 2013-06-04 2016-10-11 Infectious Disease Research Institute Compositions and methods for reducing or preventing metastasis
ES3025685T3 (en) 2014-06-17 2025-06-09 Crown Laboratories Inc Genetically modified bacteria and methods for genetic modification of bacteria
WO2017147507A1 (fr) 2016-02-24 2017-08-31 Xycrobe Therapeutics, Inc. Formulation probiotique à usage cutané
EP3668957A4 (fr) * 2017-08-17 2021-06-02 University of Delaware Compositions à base de furane et leurs procédés de fabrication
CA3183350A1 (fr) 2020-06-23 2021-12-30 Thomas M. Hitchcock Formulations cutanees probiotiques

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NL7308450A (fr) * 1972-06-20 1973-12-27
FR2269962B1 (fr) * 1974-05-06 1978-02-03 Anvar
JPS58874B2 (ja) * 1979-08-30 1983-01-08 株式会社 目黒研究所 糖蛋白ｗｅｎａｃ及びその製造法
US4436728A (en) * 1982-05-26 1984-03-13 Ribi Immunochem Research, Inc. Refined detoxified endotoxin product
US4435386A (en) * 1982-05-26 1984-03-06 Ribi Immunochem Research, Inc. Refined detoxified endotoxin product
US4436727A (en) * 1982-05-26 1984-03-13 Ribi Immunochem Research, Inc. Refined detoxified endotoxin product
CA1209504A (fr) * 1982-06-30 1986-08-12 John L. Cantrell Extrait de microorganisme soluble dans la pyridine
CA1206416A (fr) * 1982-06-30 1986-06-24 John L. Cantrell Extrait de pyridine soluble provenant de microorganismes
CA1206415A (fr) * 1982-06-30 1986-06-24 John L. Cantrell Extrait de pyridine soluble provenant de microorganismes

Also Published As

Publication number Publication date
IN157240B (fr) 1986-02-15
IL73034A (en) 1988-11-15
CA1244765A (fr) 1988-11-15
ATA302384A (de) 1987-10-15
HU192585B (en) 1987-06-29
KR850002404A (ko) 1985-05-13
NL8402902A (nl) 1985-04-16
NO843776L (no) 1985-03-25
CH664897A5 (de) 1988-04-15
SE8404707D0 (sv) 1984-09-20
AU3340084A (en) 1985-03-28
ES8608872A1 (es) 1986-07-16
FI843716A7 (fi) 1985-03-24
FI843716A0 (fi) 1984-09-21
FR2552326A1 (fr) 1985-03-29
GB8423993D0 (en) 1984-10-31
KR870000843B1 (ko) 1987-04-25
ES536167A0 (es) 1986-07-16
GB2149301A (en) 1985-06-12
AT385659B (de) 1988-05-10
DK446684A (da) 1985-03-24
DE3434766C2 (de) 1987-05-14
IT8448894A0 (it) 1984-09-24
ZA847405B (en) 1985-05-29
DE3434766A1 (de) 1986-04-30
GB2149301B (en) 1988-06-22
HUT35521A (en) 1985-07-29
DK446684D0 (da) 1984-09-19
JPS60120817A (ja) 1985-06-28
FI843716L (fi) 1985-03-24
FR2552326B1 (fr) 1988-05-13
US4663306A (en) 1987-05-05
IT1179444B (it) 1987-09-16
NZ209635A (en) 1989-01-27
AU566234B2 (en) 1987-10-15
JPS6254775B2 (fr) 1987-11-17
SE8404707L (sv) 1985-03-24

Similar Documents

Publication Publication Date Title
BE900650A (fr) Composition d'endotoxine detoxifiee raffinee et d'un extrait d'un microorganisme soluble dans la pyridine.
FR2527443B1 (fr) Composition contenant de l'endotoxine raffinee et medicament la contenant
LU91498I2 (fr) Etanercept et ses dérivés pharmaceutiquement acceptables.
ES8205231A1 (es) Procedimiento para preparar complejos de platino (iv)-diami-na
NO852872L (no) Fremgangsmaate for fremstilling av nye tetrapyrroler.
EP0719150A4 (fr) Vaccin cellulaire et procedes d'utilisation dans le traitement de tumeurs malignes solides
OA07103A (fr) Nouvelles 1,2-diaminocyclobutène-3,4-diones, leur procédé de préparation et composition pharmaceutique les contenant.
OA08694A (fr) Acides 3-pyrrolidinylthio-1-azabicyclo [3.2.0] -hept-2-ène-2-carboxyliques et procédés pour leur préparation.
FR2528050B1 (fr) Facteurs 1, 2, 3, 4 et 5 isoles purs de la teichomycine a2 utiles notamment comme medicaments antibiotiques et procede pour leur preparation
BG42837A3 (bg) Метод за получаване на имуноглобулинови производни на винка алкалоиди
ATE232394T1 (de) Verwendung von modifiziertem c-reaktiven protein zur herstellung eines medikaments zur behandlung von krebs
GB2217330B (en) Lipolytic material associated with cachexia inducing tumours, preparations,production and uses thereof.
ES2004245A6 (es) Un procedimiento para la produccion de un anticuerpo monoclonal
HUT61202A (en) Process for producing pharmaceutical compositions neutralizing procoagulant activity caused by tumour cells
DZ1390A1 (fr) Procédé de préparation de dérivés d'acides benzocycloalcényl dihydroxy alcanoïque et de médicaments les contenant.
DE69720783D1 (de) Reaktive sauerstoffverbindungen enthaltende verbindungen zur induzierung von zelldifferentiation maligner zellen so wie leukämie
ES8506806A1 (es) Procedimiento para la preparacion de una proteina hipocolesterolemicamente activa
DE3372764D1 (en) Pharmaceutical preparations containing (+)-cyanidan-3-ol derivatives, the use thereof, novel substituted (+)-cyanidan-3-ol derivatives, and processes for producing them
DE69026371D1 (de) Heilmittel und verfahren zur inhibierung der vaskularisierung von tumoren
FR2550944B1 (fr) Association pharmaceutique a base d'anticorps anticellules tumorales et de conjugues cytotoxiques, appropriee notamment pour le traitement des cancers
ZA884262B (en) Pharmaceutical composition for the treatment of tumors
EP0254593A3 (fr) Préparation et applications d'interféron gamma
FR2631829B1 (fr) Exopolysaccharides fongiques ayant une activite immunostimulante, leur procede d'obtention et composition therapeutique les contenant
IE871358L (en) Interferon for carcinoma
AU1932888A (en) Treatment of malignant tumors with 8-chloroadenosine 3',5'- cyclic phosphate, 8-aminoadenosine 3',5'-cyclic phosphate and preparation thereof

Legal Events

Date Code Title Description
RE Patent lapsed

Owner name: RIBI IMMUNOCHEM RESEARCH INC.

Effective date: 19900930